サンプル依頼リスト カート
  • English
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1750663

COPD・喘息治療の世界市場：市場規模・シェア・動向分析 (薬剤クラス別・デバイス/製品別・技術/ソフトウェア別・適応症別・流通チャネル別・地域別)、セグメント別予測 (2025年～2030年)

COPD And Asthma Therapeutics Market Size, Share & Trends Analysis Report By Drug Class, By Device/Product, By Technology/Software, By Indication, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

出版日
ページ情報
英文 120 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.35円
COPD・喘息治療の世界市場：市場規模・シェア・動向分析 (薬剤クラス別・デバイス/製品別・技術/ソフトウェア別・適応症別・流通チャネル別・地域別)、セグメント別予測 (2025年～2030年)
出版日: 2025年05月23日
発行: Grand View Research
ページ情報: 英文 120 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

COPD・喘息治療の市場動向：

世界のCOPD・喘息治療の市場規模は、2024年に923億米ドルと評価され、2025年から2030年にかけてCAGR 9.18％で成長すると予測されます。

慢性呼吸器疾患の有病率の増加は、汚染レベルの上昇、タバコ消費、高齢化によって悪化しており、気管支拡張薬、コルチコステロイド、併用療法の需要を大幅に押し上げています。

例えば、Global Initiative for Asthma（GINA）によると、喘息は2022年に世界で2億6,200万人以上が罹患し、WHOはCOPDが世界第3位の死因であると報告しています。また、高齢化社会の進展と自動車や工業用排ガスの増加が、世界のCOPD・喘息治療産業の主要な原動力となっています。工業地帯付近の大気の質の悪化は、喘息の罹患率の増加につながっています。欧州環境庁によると、2021年の大気汚染物質レベルは、世界保健機関（WHO）の大気質ガイドラインで指定されたレベルを大幅に上回りました。この推奨レベルを達成すれば、EU加盟国（EU-27）全体で、微小粒子状物質（PM2.5）への曝露に関連した25万3,000人の死亡、二酸化窒素（NO2）への曝露による5万2,000人の死亡など、相当数の死亡を防ぐことができました。さらに、オゾン（O3）への短期暴露を減らすことで、2万2,000人の死亡を減らすことができました。

COPD・喘息治療市場は、Bluetooth接続のスマート吸入器やAIベースの呼吸モニタリングプラットフォームなど、ドラッグデリバリー機器の技術進歩によっても推進され、治療アドヒアランスを高め、患者の遠隔管理を可能にしています。Propeller HealthやTevaのような企業は、薬の使用状況を追跡し、臨床医にリアルタイムでデータを送信するFDA承認のスマート吸入器を発表しています。

さらに、モバイルヘルスアプリや遠隔呼吸器ソリューションの普及が進んでおり、特に医療サービスが行き届いていない地域での医療へのアクセスが向上しています。オンライン薬局や消費者直結型デジタル・プラットフォームの拡大も治療へのアクセスを合理化し、在宅での疾病管理へのシフトを後押ししています。薬剤クラス、送達デバイス、デジタルツールのこれらの進歩を総合すると、COPD・喘息市場は2030年まで持続的な成長を遂げると予想されます。

医療費の増大、発展途上地域における医療アクセスの改善、慢性呼吸器疾患の管理を目的とした政府の支援策が、市場の可能性をさらに高めています。インドや中国などの国々における国民皆保険制度の台頭は、必要不可欠な吸入器や診断薬へのアクセスを拡大しています。例えば、中国のHealthy China 2030イニシアチブは、健康と医療における公平なアクセスと成果、医療システムの変革、テクノロジーとイノベーション、環境と気候の持続可能性という4つの戦略的柱に焦点を当てています。公平性はその基礎となる目標であり、医療制度における障壁を減らし、国全体の健康アウトカムを改善するための努力を導くものです。

COVID-19の大流行は、COPD・喘息治療業界にプラスの影響を与えました。当初は、医療へのアクセスが途絶え、肺機能検査が減少し、診断が遅れたため、治療率や処方量が低下しました。しかし、パンデミックが進行するにつれ、呼吸器の健康に対する意識が高まり、慢性肺疾患患者の重篤な転帰のリスクが高まったことで、維持療法へのアドヒアランスが高まりました。在宅医療、遠隔医療、スマート吸入器や遠隔モニタリングなどのデジタルヘルスツールへのシフトは、継続的な治療と患者の関与を支えました。市場は短期的な後退に直面したもの、パンデミックによって積極的な呼吸器ケアの重要性が最終的に強化され、長期的な成長機会につながりました。

目次

第1章 分析方法・範囲

第2章 エグゼクティブサマリー

第3章 市場の変動要因・傾向・範囲

  • 市場連関の見通し
  • 市場力学
    • 市場促進要因の分析
    • 市場抑制要因の分析
    • 業界の機会の分析
    • 業界の課題の分析
    • ケーススタディ
  • ビジネス環境分析
    • 業界分析：ポーターのファイブフォース分析
    • PESTEL分析
  • COVID-19の影響分析

第4章 COPD・喘息治療市場：薬剤クラスの推定・動向分析

  • 薬物クラスセグメントダッシュボード
  • 薬物クラス市場シェア変動分析、2024年および2030年
  • 市場規模と予測および動向分析（薬剤クラス別、2018～2030年）
    • 気管支拡張薬
    • コルチコステロイド
    • ロイコトリエン修飾薬
    • 抗IgE・抗ILモノクローナル抗体
    • 併用療法
    • その他

第5章 COPD・喘息治療市場：デバイス/製品別の推定・動向分析

  • デバイス/製品別のダッシュボード
  • 市場シェア・変動分析、デバイス/製品別（2024年・2030年）
  • 市場規模・予測・動向分析、デバイス/製品別（2018～2030年）
  • 吸入器
    • 吸入器市場（2018～2030年）
  • ネブライザー
    • ネブライザー市場（2018～2030年）
  • 酸素療法装置
    • 酸素療法装置市場（2018～2030年）

第6章 COPD・喘息治療市場：技術/ソフトウェア別の推定・動向分析

  • 技術/ソフトウェア別のダッシュボード
  • 市場シェア・変動分析、技術/ソフトウェア別（2024年・2030年）
  • 市場規模・予測・動向分析、技術/ソフトウェア別（2018～2030年）
  • Bluetooth接続型スマート吸入器
    • Bluetooth接続型スマート吸入器市場（2018～2030年）
  • AIベース呼吸モニタリングプラットフォーム
    • AIベース呼吸モニタリングプラットフォーム市場（2018～2030年）
  • 症状追跡用モバイルアプリ
    • 症状追跡用モバイルアプリ市場（2018～2030年）
  • デジタル遵守・リマインダーシステム
    • デジタル遵守・リマインダーシステム市場（2018～2030年）
  • 遠隔肺疾患ソリューション
    • 遠隔肺疾患ソリューション市場（2018～2030年）

第7章 COPD・喘息治療市場：適応症別の推定・動向分析

  • 適応症別のダッシュボード
  • 市場シェア・変動分析、適応症別（2024年・2030年）
  • 市場規模・予測・動向分析、適応症別（2018～2030年）
  • 喘息
    • 喘息市場（2018～2030年）
  • COPD
    • COPD市場（2018～2030年）

第8章 COPD・喘息治療市場：流通チャネル別の推定・動向分析

  • 流通チャネル別のダッシュボード
  • 市場シェア・変動分析、流通チャネル別（2024年・2030年）
  • 市場規模・予測・動向分析、流通チャネル別（2018～2030年）
  • 病院薬局
    • 病院薬局市場（2018～2030年）
  • 小売薬局
    • 小売薬局市場（2018～2030年）
  • オンライン薬局
    • ドラッグストア市場（2018～2030年）

第9章 COPD・喘息治療市場：地域別の推定・動向分析

  • 地域市場ダッシュボード
  • 地域市場：主なポイント
  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • デンマーク
    • スウェーデン
    • ノルウェー
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • 韓国
    • オーストラリア
    • タイ
  • ラテンアメリカ
    • ブラジル
    • アルゼンチン
  • 中東・アフリカ
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第10章 競合情勢

  • 参入企業の概要
  • 企業の市況分析
  • 企業分類
  • 戦略マッピング
  • 企業プロファイル/上場企業
    • Teva Pharmaceutical Industries Ltd.
    • GSK plc
    • Merck &Co., Inc.
    • F. Hoffmann-La Roche Ltd
    • AstraZeneca
    • Boehringer Ingelheim International GmbH
    • Sanofi
    • Koninklijke Philips NV
    • BD
    • Covis Pharma
    • Findair Sp. z oo
    • Novartis AG
    • F. Hoffmann-La Roche Ltd
    • Cipla Ltd.
    • Chiesi Air
図表

List of Tables

  • Table 1. List of secondary sources
  • Table 2. List of abbreviations
  • Table 3. North America COPD and asthma therapeutics market, by country, 2018 - 2030 (USD Million)
  • Table 4. North America COPD and asthma therapeutics market, drug class, 2018 - 2030 (USD Million)
  • Table 5. North America COPD and asthma therapeutics market, by device/product, 2018 - 2030 (USD Million)
  • Table 6. North America COPD and asthma therapeutics market, by technology/software, 2018 - 2030 (USD Million)
  • Table 7. North America COPD and asthma therapeutics market, by indication scope, 2018 - 2030 (USD Million)
  • Table 8. North America COPD and asthma therapeutics market, by distribution channel scope, 2018 - 2030 (USD Million)
  • Table 9. U.S. COPD and asthma therapeutics market, drug class, 2018 - 2030 (USD Million)
  • Table 10. U.S. COPD and asthma therapeutics market, by device/product, 2018 - 2030 (USD Million)
  • Table 11. U.S. COPD and asthma therapeutics market, by technology/software, 2018 - 2030 (USD Million)
  • Table 12. U.S. COPD and asthma therapeutics market, by indication scope, 2018 - 2030 (USD Million)
  • Table 13. U.S. COPD and asthma therapeutics market, by distribution channel scope, 2018 - 2030 (USD Million)
  • Table 14. Canada COPD and asthma therapeutics market, drug class, 2018 - 2030 (USD Million)
  • Table 15. Canada COPD and asthma therapeutics market, by device/product, 2018 - 2030 (USD Million)
  • Table 16. Canada COPD and asthma therapeutics market, by technology/software, 2018 - 2030 (USD Million)
  • Table 17. Canada COPD and asthma therapeutics market, by indication scope, 2018 - 2030 (USD Million)
  • Table 18. Canada COPD and asthma therapeutics market, by distribution channel scope, 2018 - 2030 (USD Million)
  • Table 19. Mexico COPD and asthma therapeutics market, drug class, 2018 - 2030 (USD Million)
  • Table 20. Mexico COPD and asthma therapeutics market, by device/product, 2018 - 2030 (USD Million)
  • Table 21. Mexico COPD and asthma therapeutics market, by technology/software, 2018 - 2030 (USD Million)
  • Table 22. Mexico COPD and asthma therapeutics market, by indication scope, 2018 - 2030 (USD Million)
  • Table 23. Mexico COPD and asthma therapeutics market, by distribution channel scope, 2018-
  • Table 24. Europe COPD and asthma therapeutics market, drug class, 2018 - 2030 (USD Million)
  • Table 25. Europe COPD and asthma therapeutics market, by device/product, 2018 - 2030 (USD Million)
  • Table 26. Europe COPD and asthma therapeutics market, by technology/software, 2018 - 2030 (USD Million)
  • Table 27. Europe COPD and asthma therapeutics market, by indication scope, 2018 - 2030 (USD Million)
  • Table 28. Europe COPD and asthma therapeutics market, by distribution channel scope, 2018 - 2030 (USD Million)
  • Table 29. UK COPD and asthma therapeutics market, drug class, 2018 - 2030 (USD Million)
  • Table 30. UK COPD and asthma therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 31. UK COPD and asthma therapeutics market, by technology/software, 2018 - 2030 (USD Million)
  • Table 32. UK COPD and asthma therapeutics market, by indication scope, 2018 - 2030 (USD Million)
  • Table 33. UK COPD and asthma therapeutics market, by distribution channel scope, 2018 - 2030 (USD Million)
  • Table 34. Germany COPD and asthma therapeutics market, drug class, 2018 - 2030 (USD Million)
  • Table 35. Germany COPD and asthma therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 36. Germany COPD and asthma therapeutics market, by technology/software, 2018 - 2030 (USD Million)
  • Table 37. Germany COPD and asthma therapeutics market, by indication scope, 2018 - 2030 (USD Million)
  • Table 38. Germany COPD and asthma therapeutics market, by distribution channel scope, 2018 - 2030 (USD Million)
  • Table 39. France COPD and asthma therapeutics market, drug class, 2018 - 2030 (USD Million)
  • Table 40. France COPD and asthma therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 41. France COPD and asthma therapeutics market, by technology/software, 2018 - 2030 (USD Million)
  • Table 42. France COPD and asthma therapeutics market, by indication scope, 2018 - 2030 (USD Million)
  • Table 43. France COPD and asthma therapeutics market, by distribution channel scope, 2018 - 2030 (USD Million)
  • Table 44. Italy COPD and asthma therapeutics market, drug class, 2018 - 2030 (USD Million)
  • Table 45. Italy COPD and asthma therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 46. Italy COPD and asthma therapeutics market, by technology/software, 2018 - 2030 (USD Million)
  • Table 47. Italy COPD and asthma therapeutics market, by indication scope, 2018 - 2030 (USD Million)
  • Table 48. Italy COPD and asthma therapeutics market, by distribution channel scope, 2018 - 2030 (USD Million)
  • Table 49. Spain COPD and asthma therapeutics market, drug class, 2018 - 2030 (USD Million)
  • Table 50. Spain COPD and asthma therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 51. Spain COPD and asthma therapeutics market, by technology/software, 2018 - 2030 (USD Million)
  • Table 52. Spain COPD and asthma therapeutics market, by indication scope, 2018 - 2030 (USD Million)
  • Table 53. Spain COPD and asthma therapeutics market, by distribution channel scope, 2018 - 2030 (USD Million)
  • Table 54. Norway COPD and asthma therapeutics market, drug class, 2018 - 2030 (USD Million)
  • Table 55. Norway COPD and asthma therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 56. Norway COPD and asthma therapeutics market, by technology/software, 2018 - 2030 (USD Million)
  • Table 57. Norway COPD and asthma therapeutics market, by indication scope, 2018 - 2030 (USD Million)
  • Table 58. Norway COPD and asthma therapeutics market, by distribution channel scope, 2018 - 2030 (USD Million)
  • Table 59. Sweden COPD and asthma therapeutics market, drug class, 2018 - 2030 (USD Million)
  • Table 60. Sweden COPD and asthma therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 61. Sweden COPD and asthma therapeutics market, by technology/software, 2018 - 2030 (USD Million)
  • Table 62. Sweden COPD and asthma therapeutics market, by indication scope, 2018 - 2030 (USD Million)
  • Table 63. Sweden COPD and asthma therapeutics market, by distribution channel scope, 2018 - 2030 (USD Million)
  • Table 64. Denmark COPD and asthma therapeutics market, drug class, 2018 - 2030 (USD Million)
  • Table 65. Denmark COPD and asthma therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 66. Denmark COPD and asthma therapeutics market, by technology/software, 2018 - 2030 (USD Million)
  • Table 67. Denmark COPD and asthma therapeutics market, by indication scope, 2018 - 2030 (USD Million)
  • Table 68. Denmark COPD and asthma therapeutics market, by distribution channel scope, 2018 - 2030 (USD Million)
  • Table 69. Asia Pacific COPD and asthma therapeutics market, by country, 2018 - 2030 (USD Million)
  • Table 70. Asia Pacific COPD and asthma therapeutics market, drug class, 2018 - 2030 (USD Million)
  • Table 71. Asia Pacific COPD and asthma therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 72. Asia Pacific COPD and asthma therapeutics market, by technology/software, 2018 - 2030 (USD Million)
  • Table 73. Asia Pacific COPD and asthma therapeutics market, by indication scope, 2018 - 2030 (USD Million)
  • Table 74. Asia Pacific COPD and asthma therapeutics market, by distribution channel scope, 2018 - 2030 (USD Million)
  • Table 75. Japan COPD and asthma therapeutics market, drug class, 2018 - 2030 (USD Million)
  • Table 76. Japan COPD and asthma therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 77. Japan COPD and asthma therapeutics market, by technology/software, 2018 - 2030 (USD Million)
  • Table 78. Japan COPD and asthma therapeutics market, by indication scope, 2018 - 2030 (USD Million)
  • Table 79. Japan COPD and asthma therapeutics market, by distribution channel scope, 2018 - 2030 (USD Million)
  • Table 80. China COPD and asthma therapeutics market, drug class, 2018 - 2030 (USD Million)
  • Table 81. China COPD and asthma therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 82. China COPD and asthma therapeutics market, by technology/software, 2018 - 2030 (USD Million)
  • Table 83. China COPD and asthma therapeutics market, by indication scope, 2018 - 2030 (USD Million)
  • Table 84. China COPD and asthma therapeutics market, by distribution channel scope, 2018 - 2030 (USD Million)
  • Table 85. India COPD and asthma therapeutics market, drug class, 2018 - 2030 (USD Million)
  • Table 86. India COPD and asthma therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 87. India COPD and asthma therapeutics market, by technology/software, 2018 - 2030 (USD Million)
  • Table 88. India COPD and asthma therapeutics market, by indication scope, 2018 - 2030 (USD Million)
  • Table 89. India COPD and asthma therapeutics market, by distribution channel scope, 2018 - 2030 (USD Million)
  • Table 90. Australia COPD and asthma therapeutics market, drug class, 2018 - 2030 (USD Million)
  • Table 91. Australia COPD and asthma therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 92. Australia COPD and asthma therapeutics market, by technology/software, 2018 - 2030 (USD Million)
  • Table 93. Australia COPD and asthma therapeutics market, by indication scope, 2018 - 2030 (USD Million)
  • Table 94. Australia COPD and asthma therapeutics market, by distribution channel scope, 2018 - 2030 (USD Million)
  • Table 95. South Korea COPD and asthma therapeutics market, drug class, 2018 - 2030 (USD Million)
  • Table 96. South Korea COPD and asthma therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 97. South Korea COPD and asthma therapeutics market, by technology/software, 2018 - 2030 (USD Million)
  • Table 98. South Korea COPD and asthma therapeutics market, by indication scope, 2018 - 2030 (USD Million)
  • Table 99. South Korea COPD and asthma therapeutics market, by distribution channel scope, 2018 - 2030 (USD Million)
  • Table 100. Thailand COPD and asthma therapeutics market, drug class, 2018 - 2030 (USD Million)
  • Table 101. Thailand COPD and asthma therapeutics market, by device/product, 2018 - 2030 (USD Million)
  • Table 102. Thailand COPD and asthma therapeutics market, by technology/software, 2018 - 2030 (USD Million)
  • Table 103. Thailand COPD and asthma therapeutics market, by indication scope, 2018 - 2030 (USD Million)
  • Table 104. Thailand COPD and asthma therapeutics market, by distribution channel scope, 2018 - 2030 (USD Million)
  • Table 105. Latin America COPD and asthma therapeutics market, by country, 2018 - 2030 (USD Million)
  • Table 106. Latin America COPD and asthma therapeutics market, drug class, 2018 - 2030 (USD Million)
  • Table 107. Latin America COPD and asthma therapeutics market, by device/product, 2018 - 2030 (USD Million)
  • Table 108. Latin America COPD and asthma therapeutics market, by technology/software, 2018 - 2030 (USD Million)
  • Table 109. Latin America COPD and asthma therapeutics market, by indication scope, 2018 - 2030 (USD Million)
  • Table 110. Latin America COPD and asthma therapeutics market, by distribution channel scope, 2018 - 2030 (USD Million)
  • Table 111. Brazil COPD and asthma therapeutics market, drug class, 2018 - 2030 (USD Million)
  • Table 112. Brazil COPD and asthma therapeutics market, by device/product, 2018 - 2030 (USD Million)
  • Table 113. Brazil COPD and asthma therapeutics market, by technology/software, 2018 - 2030 (USD Million)
  • Table 114. Brazil COPD and asthma therapeutics market, by indication scope, 2018 - 2030 (USD Million)
  • Table 115. Brazil COPD and asthma therapeutics market, by distribution channel scope, 2018 - 2030 (USD Million)
  • Table 116. Argentina COPD and asthma therapeutics market, drug class, 2018 - 2030 (USD Million)
  • Table 117. Argentina COPD and asthma therapeutics market, by device/product, 2018 - 2030 (USD Million)
  • Table 118. Argentina COPD and asthma therapeutics market, by technology/software, 2018 - 2030 (USD Million)
  • Table 119. Argentina COPD and asthma therapeutics market, by indication scope, 2018 - 2030 (USD Million)
  • Table 120. Argentina COPD and asthma therapeutics market, by distribution channel scope, 2018 - 2030 (USD Million)
  • Table 121. Middle East & Africa COPD and asthma therapeutics market, by country, 2018 - 2030 (USD Million)
  • Table 122. Middle East & Africa COPD and asthma therapeutics market, drug class, 2018 - 2030 (USD Million)
  • Table 123. Middle East & Africa COPD and asthma therapeutics market, by device/product, 2018 - 2030 (USD Million)
  • Table 124. Middle East & Africa COPD and asthma therapeutics market, by technology/software, 2018 - 2030 (USD Million)
  • Table 125. Middle East & Africa COPD and asthma therapeutics market, by indication scope, 2018 - 2030 (USD Million)
  • Table 126. Middle East & Africa COPD and asthma therapeutics market, by distribution channel scope, 2018 - 2030 (USD Million)
  • Table 127. South Africa COPD and asthma therapeutics market, drug class, 2018 - 2030 (USD Million)
  • Table 128. South Africa COPD and asthma therapeutics market, by device/product, 2018 - 2030 (USD Million)
  • Table 129. South Africa COPD and asthma therapeutics market, by technology/software, 2018 - 2030 (USD Million)
  • Table 130. South Africa COPD and asthma therapeutics market, by indication scope, 2018 - 2030 (USD Million)
  • Table 131. South Africa COPD and asthma therapeutics market, by distribution channel scope, 2018 - 2030 (USD Million)
  • Table 132. Saudi Arabia COPD and asthma therapeutics market, drug class, 2018 - 2030 (USD Million)
  • Table 133. Saudi Arabia COPD and asthma therapeutics market, by device/product, 2018 - 2030 (USD Million)
  • Table 134. Saudi Arabia COPD and asthma therapeutics market, by technology/software, 2018 - 2030 (USD Million)
  • Table 135. Saudi Arabia COPD and asthma therapeutics market, by indication scope, 2018 - 2030 (USD Million)
  • Table 136. Saudi Arabia COPD and asthma therapeutics market, by distribution channel scope, 2018 - 2030 (USD Million)
  • Table 137. UAE COPD and asthma therapeutics market, drug class, 2018 - 2030 (USD Million)
  • Table 138. UAE COPD and asthma therapeutics market, by device/product, 2018 - 2030 (USD Million)
  • Table 139. UAE COPD and asthma therapeutics market, by technology/software, 2018 - 2030 (USD Million)
  • Table 140. UAE COPD and asthma therapeutics market, by indication scope, 2018 - 2030 (USD Million)
  • Table 141. UAE COPD and asthma therapeutics market, by distribution channel scope, 2018 - 2030 (USD Million)
  • Table 142. Kuwait COPD and asthma therapeutics market, drug class, 2018 - 2030 (USD Million)
  • Table 143. Kuwait COPD and asthma therapeutics market, by device/product, 2018 - 2030 (USD Million)
  • Table 144. Kuwait COPD and asthma therapeutics market, by technology/software, 2018 - 2030 (USD Million)
  • Table 145. Kuwait COPD and asthma therapeutics market, by indication scope, 2018 - 2030 (USD Million)
  • Table 146. Kuwait COPD and asthma therapeutics market, by distribution channel scope, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 COPD and asthma therapeutics market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market formulation & validation
  • Fig. 6 Market research approaches
  • Fig. 7 Value-chain-based sizing & forecasting
  • Fig. 8 QFD modelling for market share assessment
  • Fig. 9 Commodity flow analysis
  • Fig. 10 Market snapshot
  • Fig. 11 Market segmentation (USD Million)
  • Fig. 12 Competitive landscape
  • Fig. 13 Parent market outlook (In USD Billion)
  • Fig. 14 Related/ancillary market outlook (In USD Billion)
  • Fig. 15 COPD and asthma therapeutics market dynamics
  • Fig. 16 COPD and asthma therapeutics market: Porter's five forces analysis
  • Fig. 17 COPD and asthma therapeutics market: PESTLE analysis
  • Fig. 18 COPD and asthma therapeutics market: Drug class segment dashboard
  • Fig. 19 COPD and asthma therapeutics market: Drug class market share analysis, 2024 & 2030
  • Fig. 20 Bronchodilators market, 2018 - 2030 (USD Million)
  • Fig. 21 Corticosteroids market, 2018 - 2030 (USD Million)
  • Fig. 22 Leukotriene Modifiers market, 2018 - 2030 (USD Million)
  • Fig. 23 Anti-IgE and Anti-IL Monoclonal Antibodies market, 2018 - 2030 (USD Million)
  • Fig. 24 Combination Therapy market, 2018 - 2030 (USD Million)
  • Fig. 25 Others market, 2018 - 2030 (USD Million)
  • Fig. 26 COPD and asthma therapeutics market: Device/Product segment dashboard
  • Fig. 27 COPD and asthma therapeutics market: Device/Product market share analysis, 2024 & 2030
  • Fig. 28 Inhalers market, 2018 - 2030 (USD Million)
  • Fig. 29 Nebulizers market, 2018 - 2030 (USD Million)
  • Fig. 30 Oxygen Therapy Devices market, 2018 - 2030 (USD Million)
  • Fig. 31 COPD and asthma therapeutics market: Technology/Software segment dashboard
  • Fig. 32 COPD and asthma therapeutics market: Technology/Software market share analysis, 2024 & 2030
  • Fig. 33 Smart Inhalers with Bluetooth Connectivity market, 2018 - 2030 (USD Million)
  • Fig. 34 AI-based Respiratory Monitoring Platforms market, 2018 - 2030 (USD Million)
  • Fig. 35 Mobile Apps for Symptom Tracking market, 2018 - 2030 (USD Million)
  • Fig. 36 Digital Adherence and Reminder Systems market, 2018 - 2030 (USD Million)
  • Fig. 37 Telepulmonology Solutions and Reminder Systems market, 2018 - 2030 (USD Million)
  • Fig. 38 COPD and asthma therapeutics market: Indication market share analysis, 2024 & 2030
  • Fig. 39 Asthma market, 2018 - 2030 (USD Million)
  • Fig. 40 COPD market, 2018 - 2030 (USD Million
  • Fig. 41 COPD and asthma therapeutics market revenue, by region
  • Fig. 42 Regional marketplace: Key takeaways
  • Fig. 43 North America COPD and asthma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 44 Key country dynamics
  • Fig. 45 US COPD and asthma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 46 Key country dynamics
  • Fig. 47 Canada COPD and asthma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 48 Key country dynamics
  • Fig. 49 Mexico COPD and asthma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 50 Europe COPD and asthma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 51 Key country dynamics
  • Fig. 52 UK COPD and asthma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 53 Key country dynamics
  • Fig. 54 Germany COPD and asthma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 55 Key country dynamics
  • Fig. 56 France COPD and asthma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 57 Key country dynamics
  • Fig. 58 Italy COPD and asthma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 59 Key country dynamics
  • Fig. 60 Spain COPD and asthma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 61 Key country dynamics
  • Fig. 62 Norway COPD and asthma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 63 Key country dynamics
  • Fig. 64 Sweden COPD and asthma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 65 Key country dynamics
  • Fig. 66 Denmark COPD and asthma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 67 Asia Pacific COPD and asthma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 68 Key country dynamics
  • Fig. 69 Japan COPD and asthma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 70 Key country dynamics
  • Fig. 71 China COPD and asthma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 72 Key country dynamics
  • Fig. 73 India COPD and asthma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 74 Key country dynamics
  • Fig. 75 Australia COPD and asthma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 76 Key country dynamics
  • Fig. 77 South Korea COPD and asthma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 78 Key country dynamics
  • Fig. 79 Thailand COPD and asthma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 80 Latin America COPD and asthma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 81 Key country dynamics
  • Fig. 82 Brazil COPD and asthma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 83 Key country dynamics
  • Fig. 84 Argentina COPD and asthma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 85 MEA COPD and asthma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 86 Key country dynamics
  • Fig. 87 South Africa COPD and asthma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 88 Key country dynamics
  • Fig. 89 Saudi Arabia COPD and asthma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 90 Key country dynamics
  • Fig. 91 UAE COPD and asthma therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 92 Key country dynamics
  • Fig. 93 Kuwait healthcare information system market, 2018 - 2030 (USD Million)
  • Fig. 94 Company categorization
  • Fig. 95 Company market position analysis
  • Fig. 96 Strategic framework
目次
Product Code: GVR-4-68040-589-7

COPD & Asthma Therapeutics Market Trends:

The global COPD and asthma therapeutics market size was valued at USD 92.30 billion in 2024 and is expected to grow at a CAGR of 9.18% from 2025 to 2030. The increasing prevalence of chronic respiratory conditions, exacerbated by rising pollution levels, tobacco consumption, and aging populations, is significantly boosting demand for bronchodilators, corticosteroids, and combination therapies.

For instance, according to the Global Initiative for Asthma (GINA), asthma affected over 262 million people globally in 2022, while the WHO reported that COPD was the third leading cause of death worldwide. In addition, a growing aging population coupled with increasing automotive and industrial exhaust gases remains the key driver for the global COPD and asthma therapeutics industry. Degrading air quality near industrial areas has led to an increased incidence of asthma. According to the European Environment Agency, air pollutant levels in 2021 significantly exceeded the levels specified by the World Health Organization's (WHO) air quality guidelines. Achieving these recommended levels could have prevented a significant number of deaths across EU Member States (EU-27), including 253,000 deaths linked to exposure to fine particulate matter (PM2.5) and 52,000 deaths caused by nitrogen dioxide (NO2) exposure. In addition, reducing short-term exposure to ozone (O3) could have reduced 22,000 attributable deaths.

The COPD and asthma therapeutics market is also propelled by technological advancements in drug delivery devices, such as smart inhalers with Bluetooth connectivity and AI-based respiratory monitoring platforms, which enhance treatment adherence and enable remote patient management. Companies like Propeller Health and Teva have introduced FDA-approved smart inhalers that track medication usage and transmit data to clinicians in real time.

Moreover, the growing penetration of mobile health apps and telepulmonology solutions is improving access to care, especially in underserved areas. The expansion of online pharmacies and direct-to-consumer digital platforms is also streamlining therapy access, supporting the shift towards home-based disease management. Collectively, these advancements across therapeutic classes, delivery devices, and digital tools are expected to drive sustained growth in the COPD and asthma market through 2030.

Increasing healthcare expenditure, improved access to care in developing regions, and supportive government initiatives aimed at managing chronic respiratory conditions are further enhancing market potential. The rise of universal healthcare programs in countries such as India and China is expanding access to essential inhalers and diagnostics. For instance, China's Healthy China 2030 initiative focuses on four strategic pillars: equitable access and outcomes in health and healthcare, healthcare systems transformation, technology and innovation, and environmental and climate sustainability. Equity is the foundational goal, guiding efforts to reduce barriers in healthcare systems and improve health outcomes across the country.

The COVID-19 pandemic positively impacted the COPD and asthma therapeutics industry. Initially, disruptions in healthcare access, reduced pulmonary function testing, and delayed diagnoses led to a decline in treatment rates and prescription volumes. However, as the pandemic progressed, heightened awareness of respiratory health and the increased risk of severe COVID-19 outcomes in patients with chronic lung diseases drove greater adherence to maintenance therapies. The shift toward home-based care, telemedicine, and digital health tools, such as smart inhalers and remote monitoring, supported continued treatment and patient engagement. While the market faced short-term setbacks, the pandemic ultimately reinforced the importance of proactive respiratory care, leading to long-term growth opportunities.

Global COPD And Asthma Therapeutics Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global COPD and asthma therapeutics market report based on drug class, device/product, technology/software, indication, distribution channel, and region:

  • Drug Class Outlook (Revenue, USD Million, 2018 - 2030)
  • Bronchodilators
  • Corticosteroids
  • Leukotriene Modifiers
  • Anti-IgE and Anti-IL Monoclonal Antibodies
  • Combination Therapy
  • Others
  • Device/Product Outlook (Revenue, USD Million, 2018 - 2030)
  • Inhalers
    • Dry Powder Inhalers (DPI)
    • Metered Dose Inhalers (MDI)
    • Soft Mist Inhalers (SMI)
  • Nebulizers
    • Jet
    • Mesh
    • Ultrasonic
  • Oxygen Therapy Devices
  • Technology/Software Outlook (Revenue, USD Million, 2018 - 2030)
  • Smart Inhalers with Bluetooth Connectivity
  • AI-based Respiratory Monitoring Platforms
  • Mobile Apps for Symptom Tracking
  • Digital Adherence and Reminder Systems
  • Telepulmonology Solutions
  • Indication Outlook (Revenue, USD Million, 2018 - 2030)
  • Asthma
  • COPD
  • Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Drug Stores
  • Regional Outlook (Revenue, USD Million, 2018 - 2030)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East and Africa (MEA)
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Drug Class
    • 1.2.2. Device/Product
    • 1.2.3. Technology/Software
    • 1.2.4. Indication
    • 1.2.5. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Emergence of novel biologics
      • 3.2.1.2. Growing adoption of AI technologies in diagnostics, remote monitoring, and treatment optimization.
      • 3.2.1.3. Advancements in smart inhalers and digital health tools enhancing patient adherence and outcomes.
      • 3.2.1.4. Strong pipeline of innovative drugs and fixed-dose combination therapies.
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Regulatory hurdles and lengthy approval timelines for novel therapeutics.
      • 3.2.2.2. High cost of biologics and advanced therapies
    • 3.2.3. Industry Opportunity Analysis
    • 3.2.4. Industry Challenge Analysis
    • 3.2.5. Case Studies
  • 3.3. Business Environment Analysis
    • 3.3.1. Porter's Five Forces Analysis
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTLE Analysis
  • 3.4. COVID-19 Impact Analysis

Chapter 4. COPD and Asthma Therapeutics Market: Drug Class Estimates & Trend Analysis

  • 4.1. Drug Class Segment Dashboard
  • 4.2. Drug Class Market Share Movement Analysis, 2024 & 2030
  • 4.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2018 to 2030 (USD Million)
    • 4.3.1. Bronchodilators
      • 4.3.1.1. Bronchodilators market, 2018 - 2030 (USD Million)
    • 4.3.2. Corticosteroids
      • 4.3.2.1. Corticosteroids market, 2018 - 2030 (USD Million)
    • 4.3.3. Leukotriene Modifiers
      • 4.3.3.1. Leukotriene Modifiers market, 2018 - 2030 (USD Million)
    • 4.3.4. Anti-IgE and Anti-IL Monoclonal Antibodies
      • 4.3.4.1. Anti-IgE and Anti-IL Monoclonal Antibodies market, 2018 - 2030 (USD Million)
    • 4.3.5. Combination Therapy
      • 4.3.5.1. Combination Therapy market, 2018 - 2030 (USD Million)
    • 4.3.6. Others
      • 4.3.6.1. Others market, 2018 - 2030 (USD Million)

Chapter 5. COPD and Asthma Therapeutics Market: Device/Product Estimates & Trend Analysis

  • 5.1. Device/Product Dashboard
  • 5.2. Device/Product Market Share Movement Analysis, 2024 & 2030
  • 5.3. Market Size & Forecasts and Trend Analysis, by Device/Product, 2018 to 2030 (USD Million)
  • 5.4. Inhalers
    • 5.4.1. Inhalers market, 2018 - 2030 (USD Million)
      • 5.4.1.1. Dry Powder Inhalers
      • 5.4.1.1.1.Dry Powder Inhalers market, 2018 - 2030 (USD Million)
      • 5.4.1.2. Metered Dose Inhalers
      • 5.4.1.2.1.Metered Dose Inhalers market, 2018 - 2030 (USD Million)
      • 5.4.1.3. Soft Mist Inhalers
      • 5.4.1.3.1.Soft Mist Inhalers market, 2018 - 2030 (USD Million)
  • 5.5. Nebulizers
    • 5.5.1. Nebulizers market, 2018 - 2030 (USD Million)
      • 5.5.1.1. Jet nebulizers
        • 5.5.1.1.1. Jet nebulizers market, 2018 - 2030 (USD Million)
      • 5.5.1.2. Mesh nebulizers
        • 5.5.1.2.1. Mesh nebulizers market, 2018 - 2030 (USD Million)
      • 5.5.1.3. Ultrasonic
        • 5.5.1.3.1. Ultrasonic Inhalers market, 2018 - 2030 (USD Million)
  • 5.6. Oxygen Therapy Devices
    • 5.6.1. Oxygen Therapy Devices market, 2018 - 2030 (USD Million)

Chapter 6. COPD and Asthma Therapeutics Market: Technology/Software Estimates & Trend Analysis

  • 6.1. Technology/Software Segment Dashboard
  • 6.2. Technology/Software Market Share Movement Analysis, 2024 & 2030
  • 6.3. Market Size & Forecasts and Trend Analysis, by Technology/Software, 2018 to 2030 (USD Million)
  • 6.4. Smart Inhalers with Bluetooth Connectivity
    • 6.4.1. Smart Inhalers with Bluetooth Connectivity market, 2018 - 2030 (USD Million)
  • 6.5. AI-based Respiratory Monitoring Platforms
    • 6.5.1. AI-based Respiratory Monitoring Platforms market, 2018 - 2030 (USD Million)
  • 6.6. Mobile Apps for Symptom Tracking
    • 6.6.1. Mobile Apps for Symptom Tracking market, 2018 - 2030 (USD Million)
  • 6.7. Digital Adherence and Reminder Systems
    • 6.7.1. Digital Adherence and Reminder Systems market, 2018 - 2030 (USD Million)
  • 6.8. Telepulmonology Solutions
    • 6.8.1. Telepulmonology Solutions market, 2018 - 2030 (USD Million)

Chapter 7. COPD and Asthma Therapeutics Market: Indication Estimates & Trend Analysis

  • 7.1. Indication Segment Dashboard
  • 7.2. Indication Market Share Movement Analysis, 2024 & 2030
  • 7.3. Market Size & Forecasts and Trend Analysis, by Indication, 2018 to 2030 (USD Million)
  • 7.4. Asthma
    • 7.4.1. Asthma market, 2018 - 2030 (USD Million)
  • 7.5. COPD
    • 7.5.1. COPD market, 2018 - 2030 (USD Million)

Chapter 8. COPD and Asthma Therapeutics Market: Distribution Channel Estimates & Trend Analysis

  • 8.1. Distribution Channel Segment Dashboard
  • 8.2. Distribution Channel Market Share Movement Analysis, 2024 & 2030
  • 8.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
  • 8.4. Hospital Pharmacies
    • 8.4.1. Hospital Pharmacies market, 2018 - 2030 (USD Million)
  • 8.5. Retail Pharmacies
    • 8.5.1. Retail Pharmacies market, 2018 - 2030 (USD Million)
  • 8.6. Online Pharmacies
    • 8.6.1. Drug Stores market, 2018 - 2030 (USD Million)

Chapter 9. COPD and Asthma Therapeutics Market: Regional Estimates & Trend Analysis

  • 9.1. Regional Market Dashboard
  • 9.2. Regional Market: Key Takeaways
  • 9.3. North America
    • 9.3.1. North America COPD and asthma therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
    • 9.3.2. U.S.
      • 9.3.2.1. Key country dynamic
      • 9.3.2.2. Regulatory framework
      • 9.3.2.3. Competitive insights
      • 9.3.2.4. U.S. COPD and asthma therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
    • 9.3.3. Canada
      • 9.3.3.1. Key country dynamic
      • 9.3.3.2. Regulatory framework
      • 9.3.3.3. Competitive insights
      • 9.3.3.4. Canada COPD and asthma therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
    • 9.3.4. Mexico
      • 9.3.4.1. Key country dynamic
      • 9.3.4.2. Regulatory framework
      • 9.3.4.3. Competitive insights
      • 9.3.4.4. Mexico COPD and asthma therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • 9.4. Europe
    • 9.4.1. Europe COPD and asthma therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
    • 9.4.2. Germany
      • 9.4.2.1. Key country dynamic
      • 9.4.2.2. Regulatory framework
      • 9.4.2.3. Competitive insights
      • 9.4.2.4. Germany COPD and asthma therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
    • 9.4.3. UK
      • 9.4.3.1. Key country dynamic
      • 9.4.3.2. Regulatory framework
      • 9.4.3.3. Competitive insights
      • 9.4.3.4. UK COPD and asthma therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
    • 9.4.4. France
      • 9.4.4.1. Key country dynamic
      • 9.4.4.2. Regulatory framework
      • 9.4.4.3. Competitive insights
      • 9.4.4.4. France COPD and asthma therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
    • 9.4.5. Italy
      • 9.4.5.1. Key country dynamic
      • 9.4.5.2. Regulatory framework
      • 9.4.5.3. Competitive insights
      • 9.4.5.4. Italy COPD and asthma therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
    • 9.4.6. Spain
      • 9.4.6.1. Key country dynamic
      • 9.4.6.2. Regulatory framework
      • 9.4.6.3. Competitive insights
      • 9.4.6.4. Spain COPD and asthma therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
    • 9.4.7. Denmark
      • 9.4.7.1. Key country dynamic
      • 9.4.7.2. Regulatory framework
      • 9.4.7.3. Competitive insights
      • 9.4.7.4. Denmark COPD and asthma therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
    • 9.4.8. Sweden
      • 9.4.8.1. Key country dynamic
      • 9.4.8.2. Regulatory framework
      • 9.4.8.3. Competitive insights
      • 9.4.8.4. Sweden COPD and asthma therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
    • 9.4.9. Norway
      • 9.4.9.1. Key country dynamic
      • 9.4.9.2. Regulatory framework
      • 9.4.9.3. Competitive insights
      • 9.4.9.4. Norway COPD and asthma therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • 9.5. Asia Pacific
    • 9.5.1. Asia Pacific COPD and asthma therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
    • 9.5.2. Japan
      • 9.5.2.1. Key country dynamic
      • 9.5.2.2. Regulatory framework
      • 9.5.2.3. Competitive insights
      • 9.5.2.4. Japan COPD and asthma therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
    • 9.5.3. China
      • 9.5.3.1. Key country dynamic
      • 9.5.3.2. Regulatory framework
      • 9.5.3.3. Competitive insights
      • 9.5.3.4. China COPD and asthma therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
    • 9.5.4. India
      • 9.5.4.1. Key country dynamic
      • 9.5.4.2. Regulatory framework
      • 9.5.4.3. Competitive insights
      • 9.5.4.4. India COPD and asthma therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
    • 9.5.5. South Korea
      • 9.5.5.1. Key country dynamic
      • 9.5.5.2. Regulatory framework
      • 9.5.5.3. Competitive insights
      • 9.5.5.4. South Korea COPD and asthma therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
    • 9.5.6. Australia
      • 9.5.6.1. Key country dynamic
      • 9.5.6.2. Regulatory framework
      • 9.5.6.3. Competitive insights
      • 9.5.6.4. Australia COPD and asthma therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
    • 9.5.7. Thailand
      • 9.5.7.1. Key country dynamic
      • 9.5.7.2. Regulatory framework
      • 9.5.7.3. Competitive insights
      • 9.5.7.4. Thailand COPD and asthma therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • 9.6. Latin America
    • 9.6.1. Latin America COPD and Asthma Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.6.2. Brazil
      • 9.6.2.1. Key country dynamic
      • 9.6.2.2. Regulatory framework
      • 9.6.2.3. Competitive insights
      • 9.6.2.4. Brazil COPD and asthma therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
    • 9.6.3. Argentina
      • 9.6.3.1. Key country dynamic
      • 9.6.3.2. Regulatory framework
      • 9.6.3.3. Competitive insights
      • 9.6.3.4. Argentina COPD and asthma therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • 9.7. MEA
    • 9.7.1. MEA COPD and asthma therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
    • 9.7.2. South Africa
      • 9.7.2.1. Key country dynamic
      • 9.7.2.2. Regulatory framework
      • 9.7.2.3. Competitive insights
      • 9.7.2.4. South Africa COPD and asthma therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
    • 9.7.3. Saudi Arabia
      • 9.7.3.1. Key country dynamic
      • 9.7.3.2. Regulatory framework
      • 9.7.3.3. Competitive insights
      • 9.7.3.4. Saudi Arabia COPD and asthma therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
    • 9.7.4. UAE
      • 9.7.4.1. Key country dynamic
      • 9.7.4.2. Regulatory framework
      • 9.7.4.3. Competitive insights
      • 9.7.4.4. UAE COPD and asthma therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
    • 9.7.5. Kuwait
      • 9.7.5.1. Key country dynamic
      • 9.7.5.2. Regulatory framework
      • 9.7.5.3. Competitive insights
      • 9.7.5.4. Kuwait COPD and asthma therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 10. Competitive Landscape

  • 10.1. Participant Overview
  • 10.2. Company Market Position Analysis
  • 10.3. Company Categorization
  • 10.4. Strategy Mapping
  • 10.5. Company Profiles/Listing
    • 10.5.1. Teva Pharmaceutical Industries Ltd.
      • 10.5.1.1. Overview
      • 10.5.1.2. Financial performance
      • 10.5.1.3. Product benchmarking
      • 10.5.1.4. Strategic initiatives
    • 10.5.2. GSK plc
      • 10.5.2.1. Overview
      • 10.5.2.2. Financial performance
      • 10.5.2.3. Product benchmarking
      • 10.5.2.4. Strategic initiatives
    • 10.5.3. Merck & Co., Inc.
      • 10.5.3.1. Overview
      • 10.5.3.2. Financial performance
      • 10.5.3.3. Product benchmarking
      • 10.5.3.4. Strategic initiatives
    • 10.5.4. F. Hoffmann-La Roche Ltd
      • 10.5.4.1. Overview
      • 10.5.4.2. Financial performance
      • 10.5.4.3. Product benchmarking
      • 10.5.4.4. Strategic initiatives
    • 10.5.5. AstraZeneca
      • 10.5.5.1. Overview
      • 10.5.5.2. Financial performance
      • 10.5.5.3. Product benchmarking
      • 10.5.5.4. Strategic initiatives
    • 10.5.6. Boehringer Ingelheim International GmbH
      • 10.5.6.1. Overview
      • 10.5.6.2. Financial performance
      • 10.5.6.3. Product benchmarking
      • 10.5.6.4. Strategic initiatives
    • 10.5.7. Sanofi
      • 10.5.7.1. Overview
      • 10.5.7.2. Financial performance
      • 10.5.7.3. Product benchmarking
      • 10.5.7.4. Strategic initiatives
    • 10.5.8. Koninklijke Philips N.V.
      • 10.5.8.1. Overview
      • 10.5.8.2. Financial performance
      • 10.5.8.3. Product benchmarking
      • 10.5.8.4. Strategic initiatives
    • 10.5.9. BD
      • 10.5.9.1. Overview
      • 10.5.9.2. Financial performance
      • 10.5.9.3. Product benchmarking
    • 10.5.10. Covis Pharma
      • 10.5.10.1. Overview
      • 10.5.10.2. Financial performance
      • 10.5.10.3. Product benchmarking
    • 10.5.11. Findair Sp. z o. o.
      • 10.5.11.1. Overview
      • 10.5.11.2. Financial performance
      • 10.5.11.3. Product benchmarking
    • 10.5.12. Novartis AG
      • 10.5.12.1. Overview
      • 10.5.12.2. Financial performance
      • 10.5.12.3. Product benchmarking
    • 10.5.13. F. Hoffmann-La Roche Ltd
      • 10.5.13.1. Overview
      • 10.5.13.2. Financial performance
      • 10.5.13.3. Product benchmarking
    • 10.5.14. Cipla Ltd.
      • 10.5.14.1. Overview
      • 10.5.14.2. Financial performance
      • 10.5.14.3. Product benchmarking
    • 10.5.15. Chiesi Air
      • 10.5.15.1. Overview
      • 10.5.15.2. Financial performance
      • 10.5.15.3. Product benchmarking